Passage Bio Statistics
Total Valuation
Passage Bio has a market cap or net worth of $18.35 million. The enterprise value is -$9.23 million.
| Market Cap | 18.35M |
| Enterprise Value | -9.23M |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Passage Bio has 3.21 million shares outstanding. The number of shares has increased by 0.55% in one year.
| Current Share Class | 3.21M |
| Shares Outstanding | 3.21M |
| Shares Change (YoY) | +0.55% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 48.79% |
| Float | 2.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.49.
| Current Ratio | 1.73 |
| Quick Ratio | 1.66 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -128.90% and return on invested capital (ROIC) is -53.47%.
| Return on Equity (ROE) | -128.90% |
| Return on Assets (ROA) | -39.00% |
| Return on Invested Capital (ROIC) | -53.47% |
| Return on Capital Employed (ROCE) | -233.58% |
| Weighted Average Cost of Capital (WACC) | 9.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.85% in the last 52 weeks. The beta is 1.41, so Passage Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -26.85% |
| 50-Day Moving Average | 6.07 |
| 200-Day Moving Average | 8.40 |
| Relative Strength Index (RSI) | 51.32 |
| Average Volume (20 Days) | 39,769 |
Short Selling Information
The latest short interest is 121,984, so 3.80% of the outstanding shares have been sold short.
| Short Interest | 121,984 |
| Short Previous Month | 162,626 |
| Short % of Shares Out | 3.80% |
| Short % of Float | 4.23% |
| Short Ratio (days to cover) | 1.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.21M |
| Pretax Income | -37.68M |
| Net Income | -37.68M |
| EBITDA | -37.55M |
| EBIT | -38.21M |
| Earnings Per Share (EPS) | -$11.84 |
Balance Sheet
The company has $33.34 million in cash and $5.76 million in debt, with a net cash position of $27.58 million or $8.60 per share.
| Cash & Cash Equivalents | 33.34M |
| Total Debt | 5.76M |
| Net Cash | 27.58M |
| Net Cash Per Share | $8.60 |
| Equity (Book Value) | 11.75M |
| Book Value Per Share | 3.66 |
| Working Capital | 14.64M |
Cash Flow
| Operating Cash Flow | -30.65M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 656,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -30.65M |
| FCF Per Share | -$9.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Passage Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.55% |
| Shareholder Yield | -0.55% |
| Earnings Yield | -205.33% |
| FCF Yield | -167.04% |
Analyst Forecast
The average price target for Passage Bio is $12.67, which is 121.50% higher than the current price. The consensus rating is "Hold".
| Price Target | $12.67 |
| Price Target Difference | 121.50% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |